cixutumumab
mAbexperimental
Cixutumumab (IMC-A12) is a human monoclonal antibody for the treatment of solid tumors. — Wikipedia
Clinical trial activity
45 trials · 22 clinical orgs · 0 marketing orgs
Phase 1
15
Phase 2
34
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2005 (NCT00186628)
Timeline
Indications
Studied for
- Adenocarcinoma of Lung · Phase 2
- Adrenocortical Carcinoma · Phase 2
- Brain Stem Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Breast Neoplasms, Male · Phase 1/Phase 2
- Carcinoma · Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Merkel Cell · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Chondrosarcoma · Phase 1
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Dermatofibrosarcoma · Phase 1
- Esophageal Neoplasms · Phase 2
- Fibrosarcoma · Phase 2
- Glioma · Phase 1
- Gliosarcoma · Phase 2
- Head and Neck Neoplasms · Phase 2
- Hepatoblastoma · Phase 2
- Leiomyosarcoma · Phase 2
- Leukemia, Mast-Cell · Phase 2
- Liposarcoma · Phase 2
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Melanoma · Phase 2
- Mesothelioma · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 1
- Nerve Sheath Neoplasms · Phase 2
- Neuroblastoma · Phase 2
- Neuroectodermal Tumors · Phase 2
- Neuroendocrine Tumors · Phase 2
- Osteosarcoma · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Paraganglioma · Phase 1
- Peritoneal Neoplasms · Phase 2
- Pinealoma · Phase 1
- Prostatic Neoplasms · Phase 2
- Rectal Neoplasms · Phase 2
- Retinoblastoma · Phase 2
- Rhabdomyosarcoma · Phase 2
- Sarcoma · Phase 2
- Sarcoma, Ewing · Phase 2
- Sarcoma, Synovial · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Thymoma · Phase 2
- Thyroid Neoplasms · Phase 1
- Wilms Tumor · Phase 2
Mechanism of action
- Insulin-like growth factor I receptorANTAGONIST
IGF1R antagonist
CIX binds IGF-1R with high affinity and blocks interaction between IGF-1R and its ligands, IGF-1 and -II, and induces internalization and degradation of IGF-1R.
IGF1R inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCixutumumab ↗
- ChEMBLCHEMBL1743001 ↗
Also known as
- anti-igf-1r antibody a12
- cixutumumab
- cixutumumab
- cixutumumab
- cixutumumab
- imc-12
- imc-a12
- imc-a12
- imc-a12
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01614795 | Phase 2 | Jun 1, 2012 | National Cancer Institute (NCI) |
| NCT00957853 | Phase 2 | Oct 1, 2011 | Eli Lilly, Imclone, University of Texas at Houston |
| NCT01413191 | Phase 2 | Aug 1, 2011 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT01263782 | Phase 2 | May 1, 2011 | Eli Lilly, Genentech, Imclone, University of Texas at Houston |
| NCT01232452 | Phase 2 | Apr 1, 2011 | Eli Lilly, Imclone |
| NCT01120236 | Phase 2 | Dec 1, 2010 | National Cancer Institute (NCI), Southwest Oncology Group |
| NCT01204476 | Phase 1 | Oct 1, 2010 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT01142388 | Phase 2 | Sep 1, 2010 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT01182883 | Phase 1 | Jul 28, 2010 | National Cancer Institute (NCI) |
| NCT01160458 | Phase 2 | Jun 2, 2010 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00955305 | Phase 2 | Mar 1, 2010 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT01055314 | Phase 2 | Jan 1, 2010 | National Cancer Institute (NCI) |
| NCT01061749 | Phase 1 | Nov 1, 2009 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT01007032 | Phase 1 | Nov 1, 2009 | Eli Lilly, Medidata Solutions, Parexel |
| NCT01016015 | Phase 2 | Nov 1, 2009 | Cornell University, National Cancer Institute (NCI) |
| NCT01026623 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2009 | Cornell University, National Cancer Institute (NCI) |
| NCT00986674 | Phase 2 | Sep 1, 2009 | Indiana University, National Cancer Institute (NCI) |
| NCT01008566 | Phase 1 | Aug 1, 2009 | National Cancer Institute (NCI), University of California, Davis |
| NCT00965250 | Phase 2 | Aug 1, 2009 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00887159 | Phase 2 | Jul 1, 2009 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
Showing 20 of 45 trials
Page 1 / 3
Organizations
Research & Development (22)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 27 | 27 | 2 | 2008 |
| Imclone | For profit | 10 | 7 | 2 | 2005 |
| Eli Lilly | For profit | 9 | 7 | 2 | 2007 |
| University of Texas at Houston | Academic/Hospital | 5 | 2 | 2 | 2008 |
| Cornell University | Academic/Hospital | 3 | 0 | 1 | 2008 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 3 | 0 | 1 | 2009 |
| Southwest Oncology Group | Academic/Hospital | 3 | 0 | 1 | 2008 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2009 |
| University of Chicago | Academic/Hospital | 2 | 0 | 2 | 2008 |
| Genentech | For profit | 1 | 0 | 1 | 2011 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Medidata Solutions | For profit | 1 | 0 | 1 | 2009 |
| NSABP Foundation | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Parexel | For profit | 1 | 0 | 1 | 2009 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2005 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of California, Davis | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2008 |
22 organizations
Page 1 / 2